Evidence map›Paper›PMID 25081752›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2015

Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.

Hsien-Neng Huang, Ying-Cheng Chiang, Wen-Fang Cheng, Chi-An Chen, Ming-Chieh Lin, Kuan-Ting Kuo

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. The -124C>T Mutation of theCurrent oncology (Toronto, Ont.) · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. A novel truncated form ofOncology letters · 2016
    Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hsien-Neng Huang1] Department of Pathology, College of Medicine, Graduate Institute of Pathology, National Taiwan University, Taipei, Taiwan [2] Department of Pathology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
Ying-Cheng Chiang1] Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan [2] Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Wen-Fang Cheng1] Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan [2] Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan [3] Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chi-An ChenDepartment of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Ming-Chieh LinDepartment of Pathology, College of Medicine, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.
Kuan-Ting Kuo1] Department of Pathology, College of Medicine, Graduate Institute of Pathology, National Taiwan University, Taipei, Taiwan [2] Department of Pathology, College of Medicine, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.ORCID 0000000236571652
National Taiwan University · TWNational Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, mutations of telomerase reverse transcriptase (TERT) promoter were found in several types of cancer. A few reports demonstrate TERT promoter mutations in ovarian clear cell carcinomas but endometrial clear cell carcinoma has not been studied. The aims of this study were to compare differences of molecular alterations and clinical factors, and identify their prognostic impact in endometrial and ovarian clear cell carcinomas. We evaluated mutations of the TERT promoter and PIK3CA, expression of ARID1A, and other clinicopathological factors in 56 ovarian and 14 endometrial clear cell carcinomas. We found that TERT promoter mutations were present in 21% (3/14) of endometrial clear cell carcinomas and 16% (9/56) of ovarian clear cell carcinomas. Compared with ovarian clear cell carcinomas, endometrial clear cell carcinomas showed older mean patient age (P<0.001), preserved ARID1A immunoreactivity (P=0.017) and infrequent PIK3CA mutation (P=0.025). In ovarian clear cell carcinomas, TERT promoter mutations were correlated with patient age >45 (P=0.045) and preserved ARID1A expression (P=0.003). In cases of endometrial clear cell carcinoma, TERT promoter mutations were not statistically associated with any other clinicopathological factors. In ovarian clear cell carcinoma patients with early FIGO stage (stages I and II), TERT promoter mutation was an independent prognostic factor and correlated with a shorter disease-free survival and overall survival (P=0.015 and 0.009, respectively). In recurrent ovarian clear cell carcinoma patients with early FIGO stage, TERT promoter mutations were associated with early relapse within 6 months (P=0.018). We concluded that TERT promoter mutations were present in endometrial and ovarian clear cell carcinomas. Distinct molecular alteration patterns in endometrial and ovarian clear cell carcinomas implied different processes of tumorigenesis in these morphologically similar tumors. In ovarian clear cell carcinoma of early FIGO stage, patients with TERT promoter mutation require close follow-up during the initial 6 months following chemotherapy.

Indexed as

MutationAdenocarcinoma, Clear CellAgedBase SequenceClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsDNA Mutational AnalysisEndometrial NeoplasmsFemaleHumansKaplan-Meier EstimateMiddle AgedMolecular Sequence DataNuclear ProteinsOvarian NeoplasmsPhosphatidylinositol 3-KinasesARID1A protein, humanClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsNuclear ProteinsPhosphatidylinositol 3-KinasesPIK3CA protein, humanTelomeraseTERT protein, humanTranscription Factors

Identifiers

PMID25081752
OpenAlexW1991582255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.